Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Vibor Milunovic"'
Autor:
Dora Dragčević, Tihana Duić, Ana Bojanic, Inga Mandac Smoljanovic, Marin Kursar, Slavko Gašparov, Delfa Radić-Krišto, Slobodanka Kololonić Ostojić, Marko Lucijanic, Vibor Milunovic
Publikováno v:
HemaSphere, Vol 7, p e069861c (2023)
Externí odkaz:
https://doaj.org/article/14d7a5a2b9f246a78fd88d13cdf5b838
Autor:
Irit Avivi, David H. Vesole, Julio Davila-Valls, Lidia Usnarska-Zubkiewicz, Magdalena Olszewska-Szopa, Vibor Milunovic, Bartłomiej Baumert, Bogumiła Osękowska, Anna Kopińska, Massimo Gentile, Borja Puertas-Martinez, Paweł Robak, Edvan Crusoe, Luis Gerardo Rodriguez-Lobato, Małgorzata Gajewska, Gergely Varga, Michel Delforge, Yael Cohen, Alessandro Gozzetti, Camila Pena, Chaim Shustik, Gabor Mikala, Klara Zalac, H. Denis Alexander, Peter Barth, Katja Weisel, Joaquín Martínez-López, Anna Waszczuk-Gajda, Mateusz Krzystański, Artur Jurczyszyn
Publikováno v:
Cancers, Vol 15, Iss 17, p 4359 (2023)
Background: There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational ‘real-world’ retrospective study analyzed the characteristics and outcomes of MM patients that developed SPMs.
Externí odkaz:
https://doaj.org/article/e15af33817ea4c669ab4b40891c751f9
Autor:
Davor Galusic, Sandra Basic-Kinda, Andela Pijuk, Vibor Milunovic, Barbara Dreta, Neven Franjic, Bozena Coha, Jasminka Sincic-Petricevic, Petar Gacina, Vlatko Pejsa, Marko Lucijanic, Igor Aurer
Publikováno v:
HemaSphere, Vol 6, Iss 12, p e807 (2022)
Obinutuzumab (G) has become part of front-line treatment of follicular lymphoma (FL) based on results of a large randomized study. Data on patients treated outside of clinical trials are lacking. We have retrospectively investigated efficacy and safe
Externí odkaz:
https://doaj.org/article/488124ea74b64cb9b4bf303d49492770
Autor:
Meral Beksac, Waldemar Sawicki, Roman Hájek, Jorge J. Castillo, Anna Waszczuk-Gajda, Dorotea Fantl, Lidia Usnarska-Zubkiewicz, Irit Avivi, Jacob P. Laubach, Grzegorz Charliński, Vania Hungria, Michel Delforge, Giuseppe Mele, Ravi Vij, Krzysztof Mądry, Alessandro Gozzetti, Vibor Milunovic, Paul G. Richardson, Jieqi Liu, Edvan de Queiroz Crusoe, Agoston Gyula Szabo, Iwona Hus, Anders Waage, David H. Vesole, Agnieszka Kopacz, Artur Jurczyszyn, Julio Dávila, David Jayabalan, Mark A. Fiala, Jacek Czepiel, Jakub Dębski, Erden Atilla, Norbert Grząśko, Thomas Guerrero-Garcia
Publikováno v:
Jurczyszyn, A, Castillo, J J, Avivi, I, Czepiel, J, Davila, J, Vij, R, Fiala, M A, Gozzetti, A, Grząśko, N, Milunovic, V, Hus, I, Mądry, K, Waszczuk-Gajda, A, Usnarska-Zubkiewicz, L, Dębski, J, Atilla, E, Beksac, M, Mele, G, Sawicki, W, Jayabalan, D, Charliński, G, Gyula Szabo, A, Hajek, R, Delforge, M, Kopacz, A, Fantl, D, Waage, A, Crusoe, E, Hungria, V, Richardson, P, Laubach, J, Guerrero-Garcia, T, Liu, J & Vesole, D H 2019, ' Secondary plasma cell leukemia : a multicenter retrospective study of 101 patients ', Leukemia and Lymphoma, vol. 60, no. 1, pp. 118-123 . https://doi.org/10.1080/10428194.2018.1473574
This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who receiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a3a648a5b6a94ec452aeb9c9e1d82f
https://ruj.uj.edu.pl/xmlui/handle/item/95218
https://ruj.uj.edu.pl/xmlui/handle/item/95218
Autor:
Jorge J. Castillo, K. Martin Kortüm, Chor S. Chim, Mark A. Fiala, Ravi Vij, Vibor Milunovic, Max Bittrich, Julio Dávila, Edvan de Queiroz Crusoe, Roman Hájek, Katarzyna Wiśniewska-Piąty, David H. Vesole, Jieqi Liu, Pawel Robak, Anna Waszczuk-Gajda, Hareth Nahi, Małgorzata Raźny, Daria Zawirska, David Jayabalan, Artur Jurczyszyn
Publikováno v:
Leukemialymphoma. 60(2)
A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age o
Autor:
Vibor Milunović
Publikováno v:
Medicina, Vol 60, Iss 2, p 344 (2024)
Hodgkin lymphoma is characterized by a high cure rate in the modern era of medicine regardless of stage, but patients suffer from a high risk of comorbidity associated with the administered therapy. The main aim of this review article is to assess an
Externí odkaz:
https://doaj.org/article/4d1155021eb04469ba42c1b409969305
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Gabor Mikala, Julio Dávila, Sophia Glickman, Alessandro Gozzetti, Irit Avivi, Mor Seny Gueye, Massimo Gentile, Sarah Goldman-Mazur, Artur Jurczyszyn, Yael C Cohen, Anna Waszczuk-Gajda, Jakub Radocha, Laurent Garderet, Anna Suska, Renata Guzicka Kazmierczak, David Jayabalan, Iwona Hus, Ruben Niesvizky, Vibor Milunovic, Katarzyna Wiśniewska-Piąty, Jorge J. Castillo, Lidia Usnarska-Zubkiewicz
Publikováno v:
Blood. 132:2004-2004
Background: Hematogenous extramedullary multiple myeloma (HEMM), though rare, is mainly observed in MM patients at relapse. The current study assesses the characteristics and outcomes of patients with MM who develop HEMM in the novel agent era. Metho
Autor:
Vibor Milunović, Ida Hude, Goran Rinčić, Davor Galušić, Aron Grubešić, Marko Martinović, Nika Popović, Sunčana Divošević, Klara Brčić, Marin Međugorac, Luka Kužat, Dejan Strahija, Stefan Mrđenović, Inga Mandac Smoljanović, Delfa Radić-Krišto, Slavko Gašparov, Igor Aurer, Slobodanka Ostojić Kolonić
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2917 (2022)
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials. Prior to treatment initiatio
Externí odkaz:
https://doaj.org/article/74e8d76b553144d3adb32d6f43e07fdb
Autor:
Martina Bogeljić Patekar, Vibor Milunović, Karla Mišura Jakobac, Dražen Perica, Inga Mandac Rogulj, Marin Kursar, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica, Vol 57., Iss 3., Pp 542-553 (2018)
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for ritu
Externí odkaz:
https://doaj.org/article/a532d7dede5040d49da04c819b38aa99